How to Get Evenity (Romosozumab) in Kentucky

What Is Romosozumab and Why Does It Matter for Kentucky Patients?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab has a dual mechanism: it stimulates new bone formation while simultaneously reducing bone resorption. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk for fracture 1.

Kentucky has a pronounced osteoporosis burden. The state ranks among the highest nationally for hip fracture rates in adults aged 65 and older, driven partly by high rates of vitamin D insufficiency and tobacco use 2. The ARCH trial (N=4,093), published in the New England Journal of Medicine, demonstrated that romosozumab followed by alendronate reduced new vertebral fractures by 48% compared to alendronate alone at 24 months 3. For patients who have already fractured or whose T-scores fall at or below -2.5 with additional risk factors, romosozumab represents a first-line anabolic option before transitioning to long-term antiresorptive therapy.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend anabolic-first therapy for patients at "very high" fracture risk, stating: "Patients with very high fracture risk should be considered for initial treatment with an osteoanabolic agent, including romosozumab, followed by an antiresorptive" 4.

Step-by-Step: Getting a Romosozumab Prescription in Kentucky

Start with a bone density evaluation. A central DEXA scan of the hip and lumbar spine is the standard diagnostic test, and your prescriber will use the resulting T-score alongside your clinical fracture history to determine eligibility. Romosozumab is FDA-indicated for postmenopausal women at high fracture risk, typically defined as a T-score of -2.5 or lower, a history of fragility fracture, or a FRAX 10-year major osteoporotic fracture probability exceeding 20% 5.

Kentucky allows MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe romosozumab. NPs in Kentucky have full practice authority after meeting collaborative requirements for the first four years of licensure, so they can independently manage osteoporosis treatment after that period. The prescribing pathway typically follows this sequence:

1. DEXA scan and fracture risk assessment using FRAX or similar validated tool.
2. Baseline laboratory work including serum calcium, 25-hydroxyvitamin D, renal function (eGFR), and a cardiovascular risk evaluation.
3. Cardiovascular screening because romosozumab carries a boxed warning for increased risk of myocardial infarction and stroke. Patients who have had a cardiovascular event within the preceding 12 months are generally excluded 1.
4. Prior authorization submission to the patient's insurer, including DEXA results, fracture history, and documentation of prior antiresorptive failure or intolerance if required.
5. Injection scheduling at a clinic, infusion center, or through a home health service. Each dose consists of two 105 mg prefilled syringes administered consecutively.

The entire evaluation can often be completed within two to three weeks if labs and DEXA are ordered at the initial visit.

Telehealth Options for Evenity in Kentucky

Kentucky permits telehealth prescribing of romosozumab. Yes, this includes controlled and specialty medications when prescribed within the applicable standard of care. Kentucky House Bill 140 (enacted 2020) established parity for telehealth services and removed prior in-person visit requirements for most specialties 6.

A telehealth endocrinologist or rheumatologist can review your DEXA results, order necessary labs at a local draw station, perform a cardiovascular risk assessment via clinical history, and submit the prior authorization. The physical injections still require either an in-person clinic visit, a home health nurse, or patient self-administration training. Romosozumab is a subcutaneous injection, not an infusion, so self-administration is possible after proper instruction.

Several national telehealth platforms now connect Kentucky patients with board-certified endocrinologists who prescribe romosozumab. HealthRX's telehealth network offers this service with licensed providers in the state. The initial consultation, lab review, and prior authorization support can all occur remotely. Only the monthly injection itself requires a physical touchpoint.

Wait times through telehealth are often shorter. An initial consultation can typically be scheduled within five to seven business days, compared to four to eight weeks for a new-patient appointment with a Kentucky-based endocrinologist in person.

Prior Authorization Requirements in Kentucky

Most commercial insurers in Kentucky require prior authorization for romosozumab. The documentation package typically includes:

Clinical documentation: A central DEXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip. Some insurers accept a T-score between -1.0 and -2.5 if the patient has had a fragility fracture.

Fracture history: Radiographic or clinical evidence of prior vertebral, hip, or other osteoporotic fracture. The FRAME trial (N=7,180) showed romosozumab reduced new vertebral fractures by 73% at 12 months compared to placebo (0.5% vs. 1.8%, P<0.001) 7. Citing this data in appeals can support medical necessity.

Prior therapy failure or intolerance: Many Kentucky commercial plans require documentation that the patient tried and failed, or is intolerant to, at least one oral bisphosphonate (alendronate or risedronate) before approving romosozumab. Some plans also require evidence of denosumab failure.

Cardiovascular clearance: A statement confirming no myocardial infarction or stroke within the past 12 months. Some plans require a formal cardiology clearance note.

Kentucky Medicaid does not cover romosozumab as of 2026. Patients on Medicaid may need to pursue manufacturer assistance programs or appeal through a fair hearing process. Amgen's Evenity patient support program (Amgen Assist) offers copay cards for commercially insured patients and may provide free drug for uninsured or underinsured individuals.

Dr. Bart Clarke, an endocrinologist at Mayo Clinic and former president of the American Society for Bone and Mineral Research, has noted: "The prior authorization process for anabolic agents like romosozumab is often the single biggest barrier to timely treatment for high-risk fracture patients" 8.

Pharmacy Access and Specialty Distribution in Kentucky

Romosozumab is classified as a specialty medication. It is not stocked at standard retail pharmacies. Patients in Kentucky will fill their prescriptions through one of three channels:

Specialty pharmacies: National specialty pharmacies such as CVS Specialty, Accredo (Express Scripts), and OptumRx Specialty ship temperature-controlled romosozumab directly to patients or their prescribers' offices. Most commercial insurance plans mandate use of a preferred specialty pharmacy.

503A compounding pharmacies: Kentucky licenses 503A compounding pharmacies that can prepare patient-specific prescriptions. These pharmacies may offer romosozumab fulfillment in certain cases, though romosozumab is a biologic and is not compounded. 503A pharmacies in Kentucky may assist with ancillary compounded medications related to bone health (calcium, vitamin D formulations) but the Evenity product itself must be dispensed as the FDA-approved biologic.

Buy-and-bill through physician offices: Some endocrinology and rheumatology practices in Kentucky purchase romosozumab directly and administer it in-office, billing the insurer under the medical benefit (J-code J3111) rather than the pharmacy benefit. This approach can sometimes bypass pharmacy prior authorization and may reduce patient out-of-pocket costs depending on the plan's medical vs. pharmacy benefit structure.

Shipping within Kentucky typically takes two to three business days from specialty pharmacies. Cold-chain requirements mean the medication arrives in insulated packaging with temperature monitors. Patients should verify that someone is available to receive and refrigerate the shipment on the delivery date.

Cost, Insurance, and Financial Assistance in Kentucky

The wholesale acquisition cost of romosozumab is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-dose course 9. Actual patient costs vary by insurance design.

Commercial insurance: With prior authorization approval, most Kentucky commercial plans cover romosozumab under either the specialty pharmacy benefit or the medical benefit (buy-and-bill). Copays range from $0 with the Amgen copay card to several hundred dollars per injection depending on coinsurance rates. The Amgen Evenity copay program can reduce out-of-pocket costs to as low as $5 per month for eligible commercially insured patients.

Medicare Part B: When administered in a physician's office, romosozumab is billed under Medicare Part B. Patients pay 20% coinsurance after meeting the Part B deductible, which translates to approximately $365 per injection without supplemental coverage. Medicare Supplement (Medigap) plans may cover this coinsurance. The FRAME trial data showing 73% vertebral fracture reduction supports Medicare coverage decisions 7.

Kentucky Medicaid: Not covered. Patients should explore Amgen Assist, which may provide the drug at no cost for those who meet income and insurance criteria.

Uninsured patients: Amgen's patient assistance program provides free Evenity to qualifying uninsured patients with household incomes at or below 300% of the federal poverty level.

Required Labs and Monitoring During Treatment

Before the first romosozumab injection, your prescriber should order these baseline labs:

• Serum calcium (corrected for albumin): Hypocalcemia must be corrected before starting treatment. Romosozumab can lower serum calcium, and patients with pre-existing hypocalcemia, vitamin D deficiency, or renal impairment face higher risk 1.
• 25-hydroxyvitamin D: Levels should be above 30 ng/mL before initiating therapy. Repletion with 50 to 000 IU ergocalciferol weekly for 8 weeks is standard if levels fall below 20 ng/mL 10.
• eGFR / serum creatinine: Renal function assessment. Romosozumab has not been studied in patients with eGFR <30 mL/min/1.73m².
• Complete metabolic panel: To assess liver function and electrolytes.
• DEXA scan: Central (hip and spine) DEXA within the preceding 24 months.

During the 12-month treatment course, monitoring includes serum calcium at month 1 and as clinically indicated, a repeat DEXA at month 12 or shortly after completion, and ongoing cardiovascular symptom monitoring at each injection visit.

The Endocrine Society recommends that all patients completing a course of romosozumab transition immediately to an antiresorptive agent (alendronate, zoledronic acid, or denosumab) to maintain the bone density gains achieved during the anabolic phase 11. The ARCH trial demonstrated that the greatest fracture reduction benefit occurred when romosozumab was followed by alendronate rather than when alendronate was used alone from the start 3.

Cardiovascular Safety: The Boxed Warning

Romosozumab carries an FDA boxed warning for potential increased risk of myocardial infarction, stroke, and cardiovascular death. This warning stems from the ARCH trial, in which cardiovascular serious adverse events occurred in 2.5% of romosozumab-treated patients vs. 1.9% of alendronate-treated patients during the 12-month double-blind period 3. The absolute risk difference was 0.6%.

The FDA label states that romosozumab "should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" and that prescribers should "consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors" 1. Kentucky has elevated cardiovascular disease prevalence compared to the national average, making this assessment particularly relevant for local patients.

A practical cardiovascular screening before romosozumab includes: review of cardiac history, blood pressure measurement, lipid panel review, and assessment of 10-year ASCVD risk using the pooled cohort equation. Patients with 10-year ASCVD risk above 20% should have a documented risk-benefit discussion in their medical record.

Transitioning After the 12-Month Course

Romosozumab is a fixed 12-dose course. It is not continued indefinitely. The bone formation effects of sclerostin inhibition wane after 12 months, and bone density gains can reverse rapidly without follow-on antiresorptive therapy.

In the ARCH trial extension data, patients who received romosozumab for 12 months followed by alendronate maintained BMD gains at the total hip through 36 months, with a cumulative 4.9% increase from baseline vs. 2.9% with alendronate alone 3. The standard transition protocol is:

• Oral bisphosphonate (alendronate 70 mg weekly or risedronate 150 mg monthly) for patients who tolerate oral therapy.
• Zoledronic acid (5 mg IV annually) for patients who cannot tolerate oral bisphosphonates or who have adherence concerns.
• Denosumab (60 mg SC every 6 months) for patients with renal impairment or bisphosphonate intolerance, though denosumab carries its own discontinuation rebound risk 12.

Your Kentucky prescriber should have the transition agent selected before you complete dose 12.